Short interest for Nagarro gives investors a sense of the degree to which investors are betting on the decline of Nagarro's stock. Short interest data is updated every two weeks.

Nagarro Stock (OTC:NGRRF), Short Interest Report

Nagarro SE is a digital engineering company. It offers application development and management, digital product engineering, artificial intelligence and machine learning, cloud solutions, digital marketing, IoT solutions, digital commerce solutions, managed services, and others. The company's geographical segment includes North America, Central Europe, Rest of Europe, and Rest of World.

Nagarro SE

<p>CIBC  analyst Paul Holden   maintains Manulife Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MFC#TSX">MFC</a>) with a Neutral and raises the price target from C$34 to C$36.</p>


News

Price Target

Analyst Ratings

TSX:MFC

CIBC Maintains Neutral on Manulife Financial, Raises Price Target to C$36

<p>Needham  analyst Serge Belanger   maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and maintains $62 price target.</p>


XENE

Needham Maintains Buy on Xenon Pharmaceuticals, Maintains $62 Price Target

<p>Wedbush  analyst Nick Setyan   maintains The One Group Hospitality (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKS#NASDAQ">STKS</a>) with a Neutral and raises the price target from $5 to $6.</p>


STKS

Wedbush Maintains Neutral on The One Group Hospitality, Raises Price Target to $6

<p>CLSA  analyst Elinor Leung   upgrades Bilibili (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>) from Outperform to Buy and raises the price target from $12.2 to $16.8.</p>


Upgrades

BILI

CLSA Upgrades Bilibili to Buy, Raises Price Target to $16.8

<p>Citigroup  analyst Ygal Arounian   maintains Ziff Davis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZD#NASDAQ">ZD</a>) with a Neutral and lowers the price target from $74 to $62.</p>


Citigroup Maintains Neutral on Ziff Davis, Lowers Price Target to $62

<p>Citigroup  analyst Jon Tower   maintains Sweetgreen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) with a Neutral and raises the price target from $25 to $28.</p>


Citigroup Maintains Neutral on Sweetgreen, Raises Price Target to $28

<p>Citigroup  analyst David Hoang   maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and lowers the price target from $62 to $60.</p>


Citigroup Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $60

<p>Citigroup  analyst Jason Bazinet   maintains AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Buy and raises the price target from $80 to $98.</p>


Citigroup Maintains Buy on AppLovin, Raises Price Target to $98

<p>Citigroup  analyst David Lebowitz   maintains Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) with a Neutral and lowers the price target from $31 to $29.</p>


NTLA

Citigroup Maintains Neutral on Intellia Therapeutics, Lowers Price Target to $29

<p>Citigroup  analyst Drew Foster   maintains HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Buy and lowers the price target from $798 to $767.</p>


HUBS

Citigroup Maintains Buy on HubSpot, Lowers Price Target to $767

<p>Citigroup  analyst George Kurosawa   maintains SPS Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPSC#NASDAQ">SPSC</a>) with a Buy and raises the price target from $213 to $222.</p>


SPSC

Citigroup Maintains Buy on SPS Commerce, Raises Price Target to $222

<p>CORRECTION: &nbsp;Benchmark analyst Cody Acree reiterates Tower Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSEM#NASDAQ">TSEM</a>) with a Buy and raises the price target from $40 to $50. - Price Target Change updated</p>


Reiteration

TSEM

CORRECTION: Benchmark Reiterates Buy on Tower Semiconductor, Raises Price Target to $50 – Price Target Change updated

<p>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) reported quarterly losses of $(2.02) per share which beat the analyst consensus estimate of $(3.53) by 42.78 percent. This is a 51.9 percent increase over losses of $(4.20) per share from the same period last year.</p>


Earnings

Earnings Beats

MBRX

Moleculin Biotech Q1 EPS $(2.02) Beats $(3.53) Estimate

<p><strong>Production, Prices and Revenue:</strong>&nbsp;&nbsp; Production for the first quarter of 2024 was 35.1 MBoe/d compared with 34.1 MBoe/d for the fourth quarter of 2023 and 32.5 MBoe/d for the corresponding period in 2023. The increase in production compared to the fourth quarter of 2023 was primarily driven by the inclusion of the Cox acquisition, which closed in January 2024 and was partially offset by natural decline. First quarter 2024 production was comprised of 15.4 thousand barrels per day ("MBbl/d") of oil (44%), 3.8 MBbl/d of natural gas liquids ("NGLs") (11%), and 96.0 million cubic feet per day ("MMcf/d") of natural gas (45%). Production in the second quarter of 2024 will be negatively impacted by planned maintenance which required shut-ins of select fields and is reflected in second quarter guidance.</p>
<p>&nbsp;</p>
<p><strong>Second Quarter and Full Year 2024 Production and Expense Guidance</strong></p>
<p>The guidance for the second quarter and full year 2024 in the table below represents the Company's current expectations. Please refer to the section entitled "Forward-Looking and Cautionary Statements" below for risk factors that could impact guidance.</p>
<p><figure class="table"><br />
<table>
<tbody>
<tr>
<td>Production</td>
<td>Second Quarter 2024</td>
<td>Full Year 2024</td>
</tr>
<tr>
<td>Oil (MBbl)</td>
<td>1,225 – 1,400</td>
<td>5,100 – 5,800</td>
</tr>
<tr>
<td>NGLs (MBbl)</td>
<td>280 – 315</td>
<td>1,150 – 1,375</td>
</tr>
<tr>
<td>Natural gas (MMcf)</td>
<td>8,800 – 10,060</td>
<td>37,000 – 44,500</td>
</tr>
<tr>
<td>Total equivalents (MBoe)</td>
<td>2,972 – 3,392</td>
<td>12,417 – 14,592</td>
</tr>
<tr>
<td>Average daily equivalents (MBoe/d)</td>
<td>32.7 – 37.3</td>
<td>33.9 – 39.9</td>
</tr>
<tr>
<td>Expenses</td>
<td>Second Quarter 2024</td>
<td>Full Year 2024</td>
</tr>
<tr>
<td>Lease operating expense ($MM)</td>
<td>83.0 – 92.0</td>
<td>295.0 – 332.0</td>
</tr>
<tr>
<td>Gathering, transportation &amp; production taxes ($MM)</td>
<td>8.1 – 8.9</td>
<td>34.5 – 39.0</td>
</tr>
<tr>
<td>General &amp; administrative – cash ($MM)</td>
<td>13.7 – 15.1</td>
<td>59.0 – 66.5</td>
</tr>
<tr>
<td>General &amp; administrative – non-cash ($MM)</td>
<td>2.9 – 3.3</td>
<td>12.5 – 14.0</td>
</tr>
<tr>
<td>DD&amp;A ($ per Boe)</td>
<td>11.4 – 12.9</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
<p></p></figure>
</p><p>W&amp;T expects substantially all taxes in 2024 to be deferred.&nbsp;</p>


Guidance

W&T Offshore Says Production In Q2 2024 Will Be Negatively Impacted By Planned Maintenance Which Required Shut-Ins Of Select Fields And Is Reflected In Q2 Guidance

<p>W&amp;T Offshore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTI#NYSE">WTI</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 150 percent decrease over losses of $(0.02) per share from the same period last year.  The company reported quarterly sales of $140.79 million which beat the analyst consensus estimate of $139.56 million by 0.88 percent.  This is a 6.88 percent increase over sales of $131.72 million the same period last year.</p>


W&T Offshore Q1 Adj $(0.05) Beats $(0.06) Estimate, Sales $140.79M Beat $139.56M Estimate

<p>Evaxion Biotech A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology&#x2122; powered vaccines, today announced that on May 7, 2024, it received a letter (the "Letter") from the Nasdaq Stock Market LLC ("Nasdaq") Listing Qualifications Department notifying the Company that it is not currently in compliance with the minimum stockholders' equity requirement.</p>


EVAX

Evaxion Received A Letter From The Nasdaq Listing Qualifications Department Notifying That It Is Not Currently In Compliance With The Minimum Stockholders' Equity Requirement

<p>Benchmark  analyst Cody Acree   reiterates Tower Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSEM#NASDAQ">TSEM</a>) with a Buy and raises the price target from $40 to $50.</p>


CORRECTION: Benchmark Reiterates Buy on Tower Semiconductor, Raises Price Target to $50

<p>Zepp Health Corporation ("Zepp" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZEPP#NYSE">ZEPP</a>), a global leader in smart wearables and health technology, today announced that it has received a letter from the New York Stock Exchange (the "NYSE") dated April 30, 2024, notifying Zepp that it is below compliance standards due to the trading price of Zepp's American depositary shares (the "ADSs").</p>


ZEPP

Zepp Health Gets NYSE Non-Compliance Letter Notifying The Co That It Is Below Compliance Standards Due To The Trading Price Of It's ADSs

<p>In the preceding three months, 7 analysts have released ratings for AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for AnaptysBio, presenting an average target of $50.0, a high estimate of $80.00, and a low estimate of $28.00. Surpassing the previous average price target of $30.00, the current average has increased by 66.67%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715374871_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A comprehensive examination of how financial experts perceive AnaptysBio is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$34.00</td>
<td>-</td>
</tr>
<tr>
<td>David Risinger</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$47.00</td>
<td>-</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$56.00</td>
<td>-</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Julian Harrison</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Alex Schwartz</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$50.00</td>
<td>-</td>
</tr>
<tr>
<td>Yasmeen Rahimi</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$80.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AnaptysBio. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of AnaptysBio compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into AnaptysBio's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ANAB/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on AnaptysBio analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Get to Know AnaptysBio Better</h2>
<p>AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).</p>
<h3>AnaptysBio: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, AnaptysBio showcased positive performance, achieving a revenue growth rate of <strong>32.27%</strong> as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> AnaptysBio's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-468.75%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> AnaptysBio's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-40.49%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> AnaptysBio's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-8.98%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> AnaptysBio's debt-to-equity ratio surpasses industry norms, standing at <strong>0.2</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ANAB

The Analyst Landscape: 7 Takes On AnaptysBio

<p>During the last three months, 5 analysts shared their evaluations of RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $54.4, with a high estimate of $60.00 and a low estimate of $48.00. This current average reflects an increase of 14.53% from the previous average price target of $47.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715374856_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive RadNet. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Ransom</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$60.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$58.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$48.00</td>
<td>-</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$51.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to RadNet. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of RadNet compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of RadNet's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of RadNet's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RDNT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on RadNet analyst ratings.</strong></a></p>
<h2>Delving into RadNet's Background</h2>
<p>RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment.</p>
<h3>RadNet's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> RadNet displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately <strong>9.51%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> RadNet's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-0.44%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-0.3%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> RadNet's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-0.07%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> RadNet's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>2.36</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


RDNT

Peeling Back The Layers: Exploring RadNet Through Analyst Insights

Nagarro SE reports 9M results

Nagarro Q3 Results: Signs Of Demand Recovery Continue

Companies in the Technology sector have received a lot of coverage today as analysts weigh in on Temenos (TMNSF – Research Report), Mynaric AG (MOY...

Analysts Offer Insights on Technology Companies: Temenos (OtherTMNSF), Mynaric AG (OtherMOYFF) and Nagarro SE (OtherNGRRF)

Companies in the Technology sector have received a lot of coverage today as analysts weigh in on Applied Materials (AMAT – Research Report), Microc...

Analysts' Opinions Are Mixed on These Technology Stocks: Applied Materials (AMAT), Microchip (MCHP) and Nagarro SE (OtherNGRRF)

In a report released on January 5, Martin Comtesse from Jefferies maintained a Buy rating on Nagarro SE (NGRRF – Research Report), with a price tar...

Jefferies Reaffirms Their Buy Rating on Nagarro SE (NGRRF)

Martin Comtesse, an analyst from Jefferies, maintained the Buy rating on Nagarro SE (NGRRF – Research Report). The associated price target is €112....

Nagarro SE: A Strong Buy Amidst Favorable FY24 Financial Outlook and Market Resilience

There's a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Workday (WDAY – Research Report) and Nagarro SE (NGR...

Analysts Are Bullish on Top Technology Stocks: Workday (WDAY), Nagarro SE (NGRRF)

Nagarro SE reports FY results

In a report released today, Andreas Wolf from Warburg Research maintained a Buy rating on Nagarro SE (NGRRF – Research Report), with a price target...

Warburg Research Sticks to Their Buy Rating for Nagarro SE (NGRRF)

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Tech has been by far the fastest-growing industry in the last two decades, with <a href="https://investorplace.com/industries/technology/">tech stocks</a> driving&nbsp;a lot&nbsp;of the hype and enthusiasm in the stock market. For years&nbsp;now, tech has been the primary engine behind the broader market&rsquo;s gains. Not only are the major tech giants continuing their relentless expansion, but we are also seeing spillover effects as technological innovations supercharge other industries.&nbsp;Fields like healthcare, manufacturing, and transportation are being reshaped by advancements in artificial intelligence, robotics, the Internet of Things, and more.</p>



<p>With so much transformative change underway, I believe now is an opportune time to invest in some&nbsp;of the&nbsp;lesser-known tech stocks before they capture Wall Street&rsquo;s attention. The tech industry is creating new companies and opportunities faster than ever before.&nbsp;While the spotlight shines brightly on Big Tech,&nbsp;there are&nbsp;plenty of up-and-coming tech firms still flying under the radar.&nbsp;These stocks remain unknown to most investors, overlooked and undervalued. However, they have massive growth potential&nbsp;ahead&nbsp;if management can execute effectively and capitalize on the&nbsp;huge&nbsp;market opportunities. Here are seven such tech stocks:</p>



<h2>Tech Stocks: X-FAB Silicon Foundries (XFABF)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/semiconductor1600b-300x169.jpg" alt="In Ultra Modern Electronic Manufacturing Factory Design Engineer in Sterile Coverall Holds Microchip with Gloves and Examines it. Semiconductor stocks to sell. Undervalued Semiconductor Stocks"><div>Source: Shutterstock</div></div><p><strong>X-FAB Silicon Foundries</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/xfabf-stock-quote/"><strong>XFABF</strong></a>) is a leading foundry group for analog/mixed-signal semiconductor applications.&nbsp;It specializes in producing and selling analog/mixed-signal IC, micro-electro-mechanical systems, and silicon carbide products for automotive, medical, industrial, communication, and consumer sectors&nbsp;worldwide.&nbsp;The company also offers design support for electronic design automation platforms. Despite the booming semiconductor industry, XFABF stock hasn&rsquo;t fared well recently. The stock is down 42% from its peak in August 2023,&nbsp;mostly&nbsp;due to the slowdown in the automotive industry, which forms core demand. As people make fewer big purchases amid high interest rates, automotive chip demand has declined significantly.</p>



<p>However,&nbsp;I believe&nbsp;the current entry point could lead to explosive returns, as we are likely at a cyclical low. A turnaround after rates eventually come down could send the stock much higher. The valuation here looks very cheap compared to growth, trading at just&nbsp;6&nbsp;times earnings. The <a href="https://www.gurufocus.com/stock/XFABF/summary">3-year revenue growth rate is 28.4%</a>, better than 84% of semiconductor peers. Future 3 to 5-year annual revenue growth is 19%, topping 92% of semiconductor companies. <em>Gurufocus</em> puts XFABF&rsquo;s fair value at $24.4 by&nbsp;the end of&nbsp;2027. I see the stars aligning for a&nbsp;major&nbsp;rebound.</p>



<h2>DroneShield Limited (DRSHF)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/stocks-to-buy-9-300x169.jpg" alt="stock button on a computer keyboard (representing best investments to start 2021. stocks to buy"><div>Source: Shutterstock</div></div><p><strong>DroneShield Limited</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/drshf-stock-quote/"><strong>DRSHF</strong></a>) has been having explosive growth in recent months, up 343% in the past six months. It&rsquo;s easy to see why when examining what this innovative company does.&nbsp;DroneShield&nbsp;engages in developing, commercializing, and selling&nbsp;hardware and software tech for drone detection and security.&nbsp;With tensions heating up and drones likely being the future of warfare, DroneShield has&nbsp;huge&nbsp;potential as a pure-play in the sector. Valuations could quickly swell as it continues&nbsp;landing&nbsp;more government contracts. Quintupling from current levels seems plausible if growth persists.</p>



<p>Its <a href="http://www.gurufocus.com/stock/DRSHF/summary">90%+ 3-year revenue growth rate</a> bests 99% of peers, and I expect rapid expansion to continue as DroneShield secures more defense contracts.&nbsp;This&nbsp;is a cutting-edge company operating in a crucial growth industry. While it has already made big moves, more upside lies ahead as drone tech becomes increasingly critical for governments worldwide. DroneShield finds itself in the right place at the right time to capitalize.</p>



<h2>Tech Stocks: Nagarro (NGRRF)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/04/ai-stocks1600-7-300x169.png" alt="AI Artificial Intelligence. Businessman using AI technology for data analysis, coding computer language with digital brain, machine learning on virtual screen, business intelligence. AI stocks"><div>Source: Tapati Rinchumrus / Shutterstock.com</div></div><p><strong>Nagarro</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/ngrrf-stock-quote/"><strong>NGRRF</strong></a>) is a digital engineering company offering services including AI and data analytics &ndash; some of the hottest sectors currently. Unfortunately, I can&rsquo;t say the same for the stock. NGRRF is down almost 70% from its peak and sliding lower. However, I foresee the company stabilizing and recovering in the coming months as double-digit revenue growth resumes. <a href="https://seekingalpha.com/symbol/NGRRF/earnings/estimates">Revenue&nbsp;is projected&nbsp;to grow from $1.1 billion in 2024 to $3 billion in 2033</a> &ndash; modest for a tech stock but with a compelling valuation.</p>



<p>Trading at 18 times earnings, I&rsquo;m banking on margin expansion from the current <a href="https://www.gurufocus.com/stock/NGRRF/summary">5.7% net margin</a> as economic conditions improve and EPS expands. Once Nagarro starts executing again, we could see huge upside. It also has an attractive 2.83% forward dividend yield while you wait. This overlooked stock could bounce back in a big way once tech recovers. With its digital engineering expertise spanning AI and analytics, Nagarro is well-positioned for the future. It currently trades at $73, but <em>Gurufocus</em> sees a fair price value of $347 by the end of 2027.</p>



<h2>Aehr Test Systems (AEHR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/10/stocks-to-buy-1600-300x169.jpg" alt="Stocks to buy: smartphone with the words &quot;buy&quot; and &quot;sell&quot; displayed on the screen. The user's finger is about to press buy. Stock charts are in the background of the image. Momentum Stocks. S&amp;P 600 Stocks to Buy. breakthrough stocks. Mario Gabbeli stocks"><div>Source: Chompoo Suriyo / Shutterstock.com</div></div><p>I have said before that the automotive industry was facing a lot of problems due to rate hikes and the ensuing slump in demand. This has caused companies that have the automotive sector as a big customer source to slump as well. <strong>Aehr Test Systems</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/aehr-stock-quote/"><strong>AEHR</strong></a>) is one such company. Aehr Test Systems is a global provider of test systems for burning-in and testing logic, optical, and memory integrated circuits. They specialize in wafer level, and package part form testing. Their systems are used in various sectors including silicon carbide (SiC), gallium nitride (GaN), and optical photonics. Automotive chips are a core part of the company&rsquo;s business and the stock has 79% from its peak in Sep. 2023.</p>



<p>That said, I think AEHR can bounce back in the coming quarters as rates increase and automotive chips come in demand again. Regardless, I would warn that this company does not have the most reliable management. Guidance was cut twice in the past two months and we are looking at growth remaining flat next year as well. Thus, near-term bleeding could happen. But if you look at the long term, AEHR is still a bargain. Once rates are cut and EV sales volumes start rising, multibagger returns aren&rsquo;t out of the question in 24-36 months. It is a profitable company with a <a href="https://www.gurufocus.com/stock/AEHR/summary">21.4% net margin</a>, so it certainly isn&rsquo;t going to zero anytime soon.</p>



<h2>Tech Stocks: Naspers (NPSNY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/02/npsny-stock-1-300x169.jpg" alt="a hand holding a phone displaying the Naspers website"><div>Source: Piotr Swat / Shutterstock.com</div></div><p><strong>Naspers</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/npsny-stock-quote/"><strong>NPSNY</strong></a>) is a multinational company operating in the consumer internet industry. It holds investments in classifieds, food delivery, payments and fintech, education, health, and e-commerce. This stock&rsquo;s performance hasn&rsquo;t been as bad as AEHR, but it has been lackluster. The stock has had many ups and downs over the past few years, but it has been essentially flat since 2017.</p>



<p>However, the core fundamentals have been strengthening, and I believe the market is heavily underpricing the stock. Many other analysts agree with me here. This company is <a href="https://seekingalpha.com/symbol/NPSNY/earnings/estimates">expected to see double-digit sales growth</a> moving forward along with EPS bouncing back by 115% this year and growing 14% next year. Moreover, this company has $20 billion in cash against $16.2 billion in debt. The debt load does cause a lot of pain due to interest payments, but as rates come down, this too should turn into a tailwind.</p>



<p>The company has substantial holding in <strong>Tencent Holdings</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/tcehy-stock-quote/"><strong>TCEHY</strong></a>) and other publicly listed, mark-to-market non-operating assets which are also expected to bounce back significantly over the coming years. It also <a href="https://www.gurufocus.com/stock/NPSNY/summary">yields a modest 0.27% dividend</a>. Gurufocus the fair price at $127 by the end of 2026. Its current price is just $34 and I don&rsquo;t see much downside risk from here.</p>



<h2>Ubiquiti (UI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/stocks-to-buy-300x169.jpg" alt='high-growth stocks an image of "Buy" on colorful buttons of the keyboard'><div>Source: Christian Chan / Shutterstock.com</div></div><p><strong>Ubiquiti</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/ui-stock-quote/"><strong>UI</strong></a>) is a technology company that manufactures and sells wireless data communication and wired products for enterprises and homes. Their industry-leading products are unified in an incredible software interface with scalable, license-free cloud management. This is another stock that is down significantly but could soon bottom out and deliver significant gains. There are&nbsp;definitely&nbsp;near-term risks here, but if you are chasing big gains in the long run, the near-term downside risk shouldn&rsquo;t matter much.</p>



<p>The company has very good margins and profitability metrics, and the dividend yield is at 2.3%. <a href="https://seekingalpha.com/symbol/UI/earnings/estimates">Growth is expected to restart next year</a>, with EPS bouncing back by 26% and revenue growing by 18.5%. This means you&rsquo;re paying just 13 times the 2025 expected EPS. I believe it can perform much better than analysts expect once the broader telecommunications industry bounces back. Most telecom companies are laden with debt and are busy with interest payments. But once cash frees up post-rate cuts, we should see growth reignite significantly. <em>Gurufocus</em> puts the fair price value for the stock at $309.</p>



<h2>Tech Stocks: Xinyi Solar Holdings (XISHY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/06/best_stocks_to_buy_now_google-300x169.jpg" alt="best investments: a hand using the touchpad on a laptop. a concept image of figures and charts is emerging from the laptop screen. overlooked stocks to buy"><div>Source: Shutterstock</div></div><p><strong>Xinyi Solar</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/xishy-stock-quote/"><strong>XISHY</strong></a>) is a photovoltaic glass manufacturer. It specializes in photovoltaic glass production and solar farm development. The company provides photovoltaic glass products to major PV module manufacturers globally. As of December 2023, it had six major photovoltaic glass production bases.</p>



<p>The entire solar sector has been seeing a downturn, but many solar companies are starting to bottom out, and there is a huge growth runway here in the long run. Xinyi has also seen its stock price decline, but I believe it can bottom out and recover soon as its top and bottom lines have continued to grow very fast. Its <a href="https://www.google.com/finance/quote/XISHY:OTCMKTS">top line grew almost 30%</a> for all of 2023. Net margin did decline by 15.4%, but with revenue continuing to grow fast, I expect that to bounce back soon.</p>



<p>Analysts <a href="https://seekingalpha.com/symbol/XISHY/earnings/estimates">expect 26.5% revenue growth this year</a> and 22% growth next year. Paying 11 times earnings seems&nbsp;really&nbsp;cheap as it also has a 4.15% forward dividend yield. Its <a href="https://www.gurufocus.com/stock/XISHY/summary">future 3 to 5-year revenue growth is better than 93% of peers</a>. All it needs right now is a margin recovery.</p>



<p><em>On the date of publication, Omor Ibne Ehsan did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines.</a></em></p>
<div><p>Omor Ibne Ehsan is a writer at InvestorPlace. He is a self-taught investor with a focus on growth and cyclical stocks that have strong fundamentals, value, and long-term potential. He also has an interest in high-risk, high-reward investments such as cryptocurrencies and penny stocks. You can follow him on <a href="https://www.linkedin.com/in/omor-ibne-ehsan-56068022b/">LinkedIn</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/04/7-unknown-tech-stocks-that-could-quintuple-your-money-in-2024/">7 Unknown Tech Stocks That Could Quintuple Your Money in 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>